Skip to main content

Table 3 Comparison of the main antibiotic prescribing outcomes in intervention and control clinics by condition

From: A pragmatic randomized trial of a primary care antimicrobial stewardship intervention in Ontario, Canada

 

Outcome

Control

Intervention

Unadjusted GEE Estimate

Adjusted GEE Estimatea

OR (95% CIb)

p

OR (95% CI)

p

URI

N

287

185

    

Total Antibiotic Prescriptions

22 (7.7%)

24 (13.0%)

1.68 (1.4, 2.02)

<0.0001

1.63 (1.2, 2.23)

<0.01

Delayed Antibiotic Prescriptions

10 (45.5%)

13 (56.5%)

0.8 (0.13, 4.96)

0.81

0.94 (0.2, 4.46)

0.94

Prescription Duration Longer than 7 daysc

6 (27.3%)

6 (27.3%)

1.72 (1.04, 2.83)

0.03

1.32 (0.11, 16.5)

0.83

Sinusitis

N

140

133

    

Total Antibiotic Prescriptions

88 (62.9%)

94 (70.7%)

1.24 (1.04, 1.48)

0.02

1.45 (0.82, 2.57)

0.2

Delayed Antibiotic Prescriptions

13 (14.8%)

23 (24.7%)

2.17 (1.3, 3.61)

<0.01

-d

Prescription Duration Longer than 7 daysc

57 (64.8%)

43 (45.7%)

0.43 (0.21, 0.89)

0.02

-

Sore Throatc

N

91

81

    

Total Antibiotic Prescriptions

52 (57.1%)

36 (44.4%)

1.0 (0.26, 3.89)

0.99

-d

Delayed Antibiotic Prescriptions

6 (11.5%)

6 (16.7%)

1.98 (0.37, 10.5)

0.42

-

Bronchitis

N

126

49

    

Total Antibiotic Prescriptions

71 (56.3%)

15 (30.6%)

0.35 (0.27, 0.46)

<0.0001

0.52 (0.19, 1.39)

0.19

Delayed Antibiotic Prescriptions

3 (4.3%)

4 (28.6%)

4.59 (0.45, 47.1)

0.2

8.48 (0.21, 338)

0.26

Prescription Duration Longer than 7 days

13 (18.3%)

3 (20.0%)

0.69 (0.08, 5.98)

0.73

0.46 (0.29, 0.73)

<0.001

Cystitis

N

119

161

    

Total Antibiotic Prescriptions

92 (77.3%)

128 (79.5%)

1.12 (0.71, 1.79)

0.62

0.96 (0.6, 1.55)

0.87

Delayed Antibiotic Prescriptions

6 (6.5%)

19 (14.8%)

3.68 (2.48, 5.47)

<0.0001

1.59 (1.08, 2.35)

0.02

Prescription Duration Longer than 7 days3

4 (4.3%)

3 (2.4%)

    
  1. aadjusted for age, sex, afterhours visit, and baseline prescribing rate, except for cystitis which involved females only b 95% confidence interval; cSore throat cases excluded from duration analyses as 10 days recommended;d Some analyses unable to be conducted due to too few cases during baseline period; eAnalyses excluded due to too few cases